Dr. Disis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
NE Pacific St
# 1959
Seattle, WA 98195Phone+1 206-598-4100
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1990 - 1993
University of Nebraska College of MedicineClass of 1986
Certifications & Licensure
WA State Medical License 1990 - 2025
IL State Medical License 1986 - 1990- American Board of Internal Medicine Internal Medicine
Clinical Trials
- HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer Start of enrollment: 1996 Apr 01
- Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer Start of enrollment: 1999 Mar 01
- S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission
- Join now to see all
Publications & Presentations
PubMed
- 3904 citationsSpecific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.Tyler J. Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng
Nature Medicine. 2004-08-22 - 57 citationsThe endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunityMarshall Behrens, Wolfgang Wagner, Christopher J. Krco, Courtney L. Erskine, Kimberly R. Kalli
Blood. 2008-02-01 - 18 citationsThe Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 DependentVy Phan-Lai, Yushe Dang, Ekram Gad, Jennifer Childs, Mary L. Disis
Clinical Cancer Research. 2016-05-01
Press Mentions
Cancer Vaccines Could Soon Become a RealityJanuary 3rd, 2023- Moderna, Merck Cancer Vaccine Combo Cuts Melanoma Recurrence by 44%December 13th, 2022
- Positive Moderna, Merck Cancer Vaccine Data Advances mRNA Promise, Shares RiseDecember 13th, 2022
- Join now to see all
Grant Support
- CTSA Infrastructure For Pediatric Clinical TrialsNational Center For Research Resources2010–2011
- Bastyr/Uw Oncomycology Translational Research CenterNational Center For Complementary &Alternative Medicine2010–2011
- Vaccinating Against IGFBP-2 To Prevent Ovarian Cancer RelapseNational Cancer Institute2009–2011
- Immune Diagnostics And Vaccine Targets: Breast Cancer Antigens From Mice To WomenNational Cancer Institute2009–2011
- Institute For Translational Health Science (KL2)National Center For Research Resources2008–2011
- CTSA Infrastructure For Pediatric ResearchNational Center For Research Resources2008–2011
- CTSA Infrastructure For Clinical TrialsNational Center For Research Resources2008–2011
- CTSA Infrastructure For AIDS ResearchNational Center For Research Resources2008–2011
- Adoptive T Cell Therapy For The Treatment Of HER2 Overexpressing CancersNational Cancer Institute2008–2011
- Institute For Translational Health Science (UL1)National Center For Research Resources2007–2011
- Institute For Translational Health Science (TL1)National Center For Research Resources2007–2011
- Optimized Ex Vivo Expansion Of Anti-Tumor TH1 And TC1 For Adoptive Immunotherapy.National Cancer Institute2009–2010
- Mechanisms Of Immunomodulatory And Anti-Tumor Actions Of Polysaccharide KrestinNational Center For Complementary &Alternative Medicine2007–2010
- Institute For Translational Health Science (Ul1): BpcaNational Center For Research Resources2009
- Institute For Translational Health ScienceNational Center For Research Resources2008–2009
- Phase II Study Of A Her-2/Neu Intracellular Domain (ICD) Peptide-Based VaccineNational Center For Research Resources2007
- Novel Methold Of Immunologic Monitoring For Assessing Cancer ImmunotherapiesNational Center For Research Resources2007
- Institute For Translational Health Science Pediatric ResearchNational Center For Research Resources2007
- Institute For Translational Health Science For Clinical TrialsNational Center For Research Resources2007
- Institute For Translational Health Science For AIDS ResearchNational Center For Research Resources2007
- Institute For Translational Health ScienceNational Center For Research Resources2007
- Safety And Immunogenicity Study Of DNA Plasmid Based Vaccine For TumorsNational Center For Research Resources2005–2007
- Phase I-II Study Of Combination Immunotherapy For Her-2/Neu Cytotoxic T CellsNational Center For Research Resources2004–2007
- Phase I Trial Of A HER2 ICD Plasmid-Based DNA VaccineNational Cancer Institute2003–2007
- Multi-Antigen Vaccines For Breast CancerNational Cancer Institute2003–2007
- Planning Grant For Institutional Clinical And Translational Science AwardNational Center For Research Resources2006
- A Feasibility Study Of Ex Vivo Expansion And Infusion Of HER2 T CellsNational Center For Research Resources2006
- Novel Methods Of Immunologic Monitoring For Assessing Cancer ImmunotherapiesNational Center For Research Resources2004–2006
- Immunologic Correlates Of Immunization For CancerNational Cancer Institute2001–2006
- Midcareer Investigator Award In Patient Oriented ResearcNational Cancer Institute2000–2004
- HER2 Vaccination For The Treatment Of CancerNational Cancer Institute2000–2004
- Antibodies As A Marker Of Effective ImmunizationNational Cancer Institute2001–2002
- H2n Peptide Vaccine In PTS With H2n Expressing CancerNational Center For Research Resources2000–2002
- Study Of A H2n Peptide Vaccine In Patients With Advanced H2n Expressing CancersNational Center For Research Resources1997–2000
- H2n Peptide Vaccines--Patients Wi/H2n Expressing CancersNational Cancer Institute1997–1999
- T Cell Immunity To Human Breast CancerNational Cancer Institute1995–1999
- Evaluation Of Immunity To Her-2/Neu In A Rodent ModelNational Cancer Institute1995–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
